“We’re not trying to be everything for everyone. Our specialized focus has been very exciting for me.”
Franco Negron, CEO of Simtra BioPharma Solutions, has transformed a 65-year sterile manufacturing legacy into an independent CDMO since the company’s carve-out from Baxter International (Baxter) in October 2023. Franco has led over $500 million in capital investments to double capacity and create mirrored capabilities across sites in Indiana, US, and Halle/Westfalen, Germany.
Franco brings industry experience from Procter & Gamble, Johnson & Johnson, Novartis, and Patheon, which became part of Thermo Fisher Scientific, where he helped shape integrated CDMO strategies.
In this PharmaSource podcast, recorded at CPHI 2025, Franco explains how Simtra is navigating supply chain challenges, tariff uncertainties, and injectable manufacturing complexity, from GLP-1s to antibody drug conjugates.
Fler avsnitt av PharmaSource Podcast
Visa alla avsnitt av PharmaSource PodcastPharmaSource Podcast med Life Science Networks finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.
